Novavax Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 23.94
Dividend & YieldN/A$ (N/A)
Beta 1.89
Market capitalization 1.32B
Operating cash flow -640.53M
ESG Scores unknown

Company description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio0.9
Working Capital7.41
Return On Equity4.96
Debt To Equity-0.92
Fixed Asset Ratio0.03
Fixed Interest Cover-79.83

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -22.35M -19.82M 434.71M 1.93B
Total Cashflows From Investing Activities 28.6M 38.49M -377.78M 100.15M
Net Borrowings -96.06M -96.06M -96.06M -127.91M
Total Cash From Financing Activities 102.81M 98.38M 984.76M 461.71M
Change To Operating Activities
Issuance Of Stock 102.81M 98.38M 881M 589.62M
Net Income -184.75M -132.69M -418.26M -1.74B
Change In Cash -53.47M 221k 566.56M 879.52M
Effect Of Exchange Rate -48k -32k 2.12M -5.29M
Total Cash From Operating Activities -184.82M -136.62M -42.54M 322.95M
Depreciation 8.16M 5.68M 4.88M 12.66M
Change To Account Receivables 1.21M -4.2M -422.69M -192.26M
Other Cashflows From Financing Activities
Change To Netincome 11.48M 14.41M 358.82M 320.42M
Capital Expenditures -1.37M -1.86M -54.62M -57.49M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -184.75M -132.69M -418.26M -1.71B
Net Income -184.75M -132.69M -418.26M -1.74B
Selling General Administrative 34.41M 34.42M 142.59M 298.36M
Gross Profit -139.51M -95.18M -271.43M -1.39B
Ebit -173.92M -129.6M -414.02M -1.69B
Operating Income -173.92M -129.6M -414.02M -1.69B
Interest Expense -13.61M -13.61M -15.14M -21.13M
Income Tax Expense 29.21M
Total Revenue 34.29M 18.66M 475.6M 1.15B
Cost Of Revenue 173.8M 113.84M 747.03M 2.53B
Total Other Income ExpenseNet -10.83M -3.1M -4.24M -27.96M
Net Income From Continuing Ops -184.75M -132.69M -418.26M -1.74B
Net Income Applicable To Common Shares -184.75M -132.69M -418.26M -1.74B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 375.91M 358.97M 955.27M 2.93B
Total Stockholder Equity -167.94M -186.02M 627.21M -351.67M
Other Current Liabilities 11.61M 1.68M 278.31M 1.43B
Total Assets 207.98M 172.96M 1.58B 2.58B
Common Stock 192k 324k 714k 764k
Other Current Assets 22.82M 7.32M 103.54M 64.98M
Retained Earnings -1.3B -1.43B -1.87B -3.62B
Treasury Stock -13.64M -15.09M -34.78M -86.45M
Cash 70.15M 78.82M 553.4M 1.52B
Total Current Liabilities 45.54M 25.8M 579.67M 2.39B
Other Stockholder Equity -11.19M -12.51M 7.02M -1.35M
Property, Plant, and Equipment 28.43M 11.45M 187.75M 268.82M
Total Current Assets 119.28M 97.25M 1.25B 2.16B
Net Tangible Assets -226.44M -242.75M 486.11M -487.92M
Net Receivables 7.5M 262.01M 454.99M
Accounts Payable 9.3M 2.91M 54.33M 127.05M


Insider Transactions

Here are the insider transactions of stock shares related to Novavax Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
ERCK STANLEY CD2022-09-26Chief Executive Officer6.55k
HERRMANN JOHN A IIID/I2022-09-26Officer4.64k
TRIZZINO JOHN JD2022-09-26Officer3.54k
HERRMANN JOHN A IIII2022-08-24Officer2k
TRIZZINO JOHN JD2022-08-19Officer655
KELLY JAMES PATRICKD2022-08-16Chief Financial Officer2.37k
HERRMANN JOHN A IIID2022-06-24Officer833
TRIZZINO JOHN JD2022-06-24Officer833
MOTT DAVID MD2022-06-17Director700
YOUNG JAMES FRANCISD2022-06-17Director1.4k
MCGLYNN MARGARET GD2022-06-17Director700
DOUGLAS RICHARD HD2022-06-17Director700
ALTON GREGG HD2022-06-17Director700
KING RACHEL KD2022-06-17Director700
MCMANUS MICHAEL A JRD2022-06-16Director700
YOUNG JAMES FRANCISSale at price 73.29 - 75.10 per share.D2022-03-31Director12.5k
HERRMANN JOHN A IIISale at price 136.82 - 144.43 per share.D2022-01-03Officer5k
HERRMANN JOHN A IIIConversion of Exercise of derivative security at price 19.08 per share.D2022-01-03Officer5k
YOUNG JAMES FRANCISSale at price 144.16 per share.D2021-12-31Director3.75k
YOUNG JAMES FRANCISConversion of Exercise of derivative security at price 25.60 per share.D2021-12-31Director3.75k
HERRMANN JOHN A IIISale at price 230.00 per share.D2021-12-20Officer5k
HERRMANN JOHN A IIIConversion of Exercise of derivative security at price 19.08 per share.D2021-12-20Officer5k
GLENN GREGORY MSale at price 168.82 - 180.62 per share.D2021-12-15Officer1.69k
GLENN GREGORY MConversion of Exercise of derivative security at price 27.60 - 46.00 per share.D2021-12-15Officer4.79k
ERCK STANLEY CD2021-12-14Chief Executive Officer6.97k
HERRMANN JOHN A IIID2021-12-14Officer2.1k
TRIZZINO JOHN JD2021-12-14Officer1.6k
DOUGLAS RICHARD HConversion of Exercise of derivative security at price 25.60 per share.D2021-12-13Director1.5k
GLENN GREGORY MSale at price 150.29 - 182.96 per share.D2021-12-07Officer8.25k
GLENN GREGORY MConversion of Exercise of derivative security at price 19.08 per share.D2021-12-07Officer8.25k
HERRMANN JOHN A IIISale at price 192.64 - 202.36 per share.D2021-12-01Officer5k
HERRMANN JOHN A IIIConversion of Exercise of derivative security at price 19.08 per share.D2021-12-01Officer5k
GLENN GREGORY MSale at price 189.98 - 211.75 per share.D2021-11-30Officer8.94k
GLENN GREGORY MConversion of Exercise of derivative security at price 19.08 per share.D2021-11-30Officer8.25k
HERRMANN JOHN A IIISale at price 228.72 per share.D2021-11-29Officer5k
HERRMANN JOHN A IIIConversion of Exercise of derivative security at price 19.08 per share.D2021-11-29Officer5k
GLENN GREGORY MSale at price 215.00 - 221.24 per share.D2021-11-26Officer2.08k
GLENN GREGORY MConversion of Exercise of derivative security at price 5.95 per share.D2021-11-26Officer3.46k
GLENN GREGORY MSale at price 196.43 - 203.62 per share.D2021-11-23Officer8.25k
GLENN GREGORY MConversion of Exercise of derivative security at price 19.08 per share.D2021-11-23Officer8.25k
GLENN GREGORY MSale at price 166.89 - 172.02 per share.D2021-11-16Officer9.43k
GLENN GREGORY MConversion of Exercise of derivative security at price 19.08 - 46.00 per share.D2021-11-16Officer9.43k
GLENN GREGORY MSale at price 164.23 - 171.48 per share.D2021-11-09Officer8.25k
GLENN GREGORY MConversion of Exercise of derivative security at price 19.08 per share.D2021-11-09Officer8.25k
HERRMANN JOHN A IIISale at price 200.00 per share.D2021-11-03Officer5k
HERRMANN JOHN A IIIConversion of Exercise of derivative security at price 19.08 per share.D2021-11-03Officer5k
GLENN GREGORY MSale at price 177.12 - 197.51 per share.D2021-11-02Officer8.25k
GLENN GREGORY MConversion of Exercise of derivative security at price 19.08 per share.D2021-11-02Officer8.25k
HERRMANN JOHN A IIISale at price 155.16 - 173.15 per share.D2021-11-01Officer5k
HERRMANN JOHN A IIIConversion of Exercise of derivative security at price 19.08 per share.D2021-11-01Officer5k
GLENN GREGORY MSale at price 145.41 - 152.16 per share.D2021-10-29Officer680

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Novavax Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Novavax Inc

Here is the result of two systematic investment strategies applied to Novavax Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Novavax Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Novavax Inc:

Novavax Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 1801.57% on the backtest period.

Performance at glance

Performance

1801.57 %

Latent gain

38322.89 $

Invested capital

2127.19 $

Annualized return

435.16 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Novavax Inc

This is the result of two momentum investment strategies applied to Novavax Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Novavax Inc

The following chart shows all the entries opened by the momentum investment system on Novavax Inc:

Novavax Inc momentum entries
  • The first momentum investment strategy would give 2295.78% of return on Novavax Inc. That represents 98212.14$ of latent gain with 4277.94$ of employed capital.
  • The second momentum investment strategy would give 1988.69% of return on Novavax Inc. That represents 60959.95$ of latent gain with 3065.33$ of employed capital.
Performance at glance (1Q Momentum)

Performance

2295.78 %

Latent gain

98212.14 $

Invested capital

4277.94 $

Annualized return

32.45 %
Performance at glance (2Q Momentum)

Performance

1988.69 %

Latent gain

60959.95 $

Invested capital

3065.33 $

Annualized return

543.36 %

Momentum equity curve on Novavax Inc

The following chart shows the equity curve of the two momentum strategies applied to Novavax Inc:

Novavax Inc momentum equity

Note: the dividends potentially given by Novavax Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Novavax Inc

The following chart shows the employed capital evolution of the two momentum strategies on Novavax Inc since the beginning:

Novavax Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Novavax Inc

Buy the dip entry openings on Novavax Inc

Novavax Inc

The performance achieved by the robo-advisor on Novavax Inc is 69.44%. That represents 305.1$ of latent gain with 439.38$ of employed capital. The following chart shows Novavax Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Novavax Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

69.44 %

Latent gain

305.1 $

Invested capital

439.38 $

Annualized return

32.45 %

Equity curve of the strategy applied to Novavax Inc

The following chart shows the result of the investment strategy applied to Novavax Inc:

Novavax Inc

Note: the dividends potentially given by Novavax Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Novavax Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Novavax Inc:

Novavax Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Novavax Inc

In this section, I will compare the three previous investment strategies applied to Novavax Inc.

Equity curve comparison on Novavax Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Novavax Inc investment strategy comparison

Employed capital comparison on Novavax Inc

Novavax Inc investment comparison

Performance comparison on Novavax Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 1801.57% 38322.89$ 2127.19$ 435.16%
Momentum 1 quarter 2295.78% 98212.14$ 4277.94$ 588.66%
Momentum 2 quarters 1988.69% 60959.95$ 3065.33$ 543.36%
Non-directional 69.44% 305.1$ 439.38$ 32.45%
Annualized return comparison

Automatic investment

435.16 %

Momentum 1Q

543.36 %

Momentum 2Q

543.36 %

Non-directional

32.45 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Novavax Inc:

Positive correlations

Most correlated stocks this year

  • Novavax Inc

  • Most correlated stocks last 3 months

  • Novavax Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • SWISS WATER DECAFFEINATED COFFEE INC
  • SUNSHINE
  • NanoVibronix Inc

  • Note: The algorithm computes the probability of correlation between Novavax Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Novavax Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Novavax Inc
    Country United States
    City Gaithersburg
    Address 21 Firstfield Road
    Phone 240 268 2000
    Website www.novavax.com
    FullTime employees 1541
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker NVAX
    Market www.nasdaq.com

    Novavax Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown